Mezigdomide,dexamethasone,bortezomib,carfilzomib
bms,takeda,amgen
congress #ims2022 | paul richardson presents data on the combination therapies mezivd, mezivd-1.0mg and mezikd, for the treatment of r/r #mm. both mezivd and mezikd demonstrated an acceptable safety profile and promising efficacy. #medicalcongress #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma